Compare · DFTX vs TRLV
DFTX vs TRLV
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Trulieve Cannabis Corp. Subordinate Voting Shares (TRLV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and TRLV operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $4.04B, about 2.2x TRLV ($1.80B).
- Over the past year, DFTX is up 170.5% and TRLV is down 18.7% - DFTX leads by 189.2 points.
- DFTX has been more active in the news (11 items in the past 4 weeks vs 8 for TRLV).
- DFTX has more recent analyst coverage (8 ratings vs 0 for TRLV).
- Company
- Definium Therapeutics Inc.
- Trulieve Cannabis Corp. Subordinate Voting Shares
- Price
- -
- -
- Market cap
- $4.04B
- $1.80B
- 1M return
- -16.94%
- -14.85%
- 1Y return
- +170.52%
- -18.70%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 11
- 8
- Recent ratings
- 8
- 0
Trulieve Cannabis Corp. Subordinate Voting Shares
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with established medical marijuana operations in Florida, Georgia, Pennsylvania, and West Virginia. Driven by a core mission to expand access to cannabis, Trulieve serves customers with innovative, high-quality branded products and exceptional experiences. With scaled operations in attractive markets and targeted expansion through its hub strategy, Trulieve is poised for accelerated growth.
Latest DFTX
- SEC Form SCHEDULE 13G filed by Definium Therapeutics Inc.
- SEC Form SCHEDULE 13G filed by Definium Therapeutics Inc.
- SEC Form 10-Q filed by Definium Therapeutics Inc.
- Definium Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form SCHEDULE 13G filed by Definium Therapeutics Inc.
- Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress
- Definium Therapeutics to Participate at Upcoming Investor Conferences
- Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026
Latest TRLV
- Trulieve to Open Medical Cannabis Dispensary in Tampa, Florida
- Trulieve Announces Preliminary Addition to the Russell 2000® and 3000® Indices
- Trulieve Announces November 2026 Event Participation
- Trulieve Expands Medical Cannabis Access through Riverside Pharmacy in Gainesville, Georgia
- SEC Form 10-Q filed by Trulieve Cannabis Corp. Subordinate Voting Shares
- Trulieve Cannabis Corp. Subordinate Voting Shares filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Trulieve Reports Third Quarter 2026 Results
- Trulieve Receives DEA Registrations for State-Licensed Medical Marijuana Operations